Alloimmunization to red cell antigens in liver and multivisceral transplant patients

Sherry Shariatmadar, Nikolaos T. Pyrsopoulos, Vladimir Vincek, Thomas A. Noto, Andreas G. Tzakis

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BACKGROUND. Alloimmunization to red blood cell (RBC) antigens can significantly impact transfusion support of patients undergoing solid-organ transplantation. This study evaluated the incidence of clinically significant RBC alloantibodies (abs) in 2000 consecutive adults receiving liver (OLTX), intestinal (ITX) or multivisceral (MVT) transplants. METHODS. From January 1991 to May 2006, 2000 patients underwent OLTX (n=1892), MVT (n=74), or ITX (n=34). Blood sample for serologic investigation was submitted to the transfusion service no later than 4 hr before surgery. The presence of clinically significant RBC abs before transplant with subsequent transfusion requirements, the incidence of delayed transfusion reactions, and de novo abs after transplant were evaluated. RESULTS. One hundred fifteen patients (5.75%) had clinically significant RBC abs before transplant, with 56.7% directed against Rh system antigens. Forty-six (40%) had multiple abs. A mean of 18 packed RBC units (U) were transfused per patient. Patients requiring >20 U (n=34) or those with multiple abs received antigen-negative units for the first 5-10 U when antibody was still present, switched to antigen-unscreened units during massive blood loss and returned to antigen-negative units for the last 5-10 U transfused. Twelve patients (0.6%) developed de novo abs posttransplant. Twenty-two (1.1%) had delayed serologic transfusion reaction. All patients were successfully managed without delay in initiation of surgery or hemolytic complications. CONCLUSION. RBC alloimmunization can present a special challenge to solid-organ transplantation. Early serologic testing of the recipient pretransplant and prompt communication between the transfusion service and transplant team facilitates successful transfusion management of these patients.

Original languageEnglish
Pages (from-to)527-531
Number of pages5
JournalTransplantation
Volume84
Issue number4
DOIs
StatePublished - Aug 1 2007

Fingerprint

Isoantibodies
Transplants
Antigens
Erythrocytes
Liver
Organ Transplantation
Cohort Studies
Communication
Antibodies
Incidence

Keywords

  • Blood transfusion
  • Liver transplantation
  • Multivisceral transplantation
  • RBC alloantibodies

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Shariatmadar, S., Pyrsopoulos, N. T., Vincek, V., Noto, T. A., & Tzakis, A. G. (2007). Alloimmunization to red cell antigens in liver and multivisceral transplant patients. Transplantation, 84(4), 527-531. https://doi.org/10.1097/01.tp.0000278093.58340.fb

Alloimmunization to red cell antigens in liver and multivisceral transplant patients. / Shariatmadar, Sherry; Pyrsopoulos, Nikolaos T.; Vincek, Vladimir; Noto, Thomas A.; Tzakis, Andreas G.

In: Transplantation, Vol. 84, No. 4, 01.08.2007, p. 527-531.

Research output: Contribution to journalArticle

Shariatmadar, S, Pyrsopoulos, NT, Vincek, V, Noto, TA & Tzakis, AG 2007, 'Alloimmunization to red cell antigens in liver and multivisceral transplant patients', Transplantation, vol. 84, no. 4, pp. 527-531. https://doi.org/10.1097/01.tp.0000278093.58340.fb
Shariatmadar, Sherry ; Pyrsopoulos, Nikolaos T. ; Vincek, Vladimir ; Noto, Thomas A. ; Tzakis, Andreas G. / Alloimmunization to red cell antigens in liver and multivisceral transplant patients. In: Transplantation. 2007 ; Vol. 84, No. 4. pp. 527-531.
@article{5e9818d6d8504785a7071778e45cf33b,
title = "Alloimmunization to red cell antigens in liver and multivisceral transplant patients",
abstract = "BACKGROUND. Alloimmunization to red blood cell (RBC) antigens can significantly impact transfusion support of patients undergoing solid-organ transplantation. This study evaluated the incidence of clinically significant RBC alloantibodies (abs) in 2000 consecutive adults receiving liver (OLTX), intestinal (ITX) or multivisceral (MVT) transplants. METHODS. From January 1991 to May 2006, 2000 patients underwent OLTX (n=1892), MVT (n=74), or ITX (n=34). Blood sample for serologic investigation was submitted to the transfusion service no later than 4 hr before surgery. The presence of clinically significant RBC abs before transplant with subsequent transfusion requirements, the incidence of delayed transfusion reactions, and de novo abs after transplant were evaluated. RESULTS. One hundred fifteen patients (5.75{\%}) had clinically significant RBC abs before transplant, with 56.7{\%} directed against Rh system antigens. Forty-six (40{\%}) had multiple abs. A mean of 18 packed RBC units (U) were transfused per patient. Patients requiring >20 U (n=34) or those with multiple abs received antigen-negative units for the first 5-10 U when antibody was still present, switched to antigen-unscreened units during massive blood loss and returned to antigen-negative units for the last 5-10 U transfused. Twelve patients (0.6{\%}) developed de novo abs posttransplant. Twenty-two (1.1{\%}) had delayed serologic transfusion reaction. All patients were successfully managed without delay in initiation of surgery or hemolytic complications. CONCLUSION. RBC alloimmunization can present a special challenge to solid-organ transplantation. Early serologic testing of the recipient pretransplant and prompt communication between the transfusion service and transplant team facilitates successful transfusion management of these patients.",
keywords = "Blood transfusion, Liver transplantation, Multivisceral transplantation, RBC alloantibodies",
author = "Sherry Shariatmadar and Pyrsopoulos, {Nikolaos T.} and Vladimir Vincek and Noto, {Thomas A.} and Tzakis, {Andreas G.}",
year = "2007",
month = "8",
day = "1",
doi = "10.1097/01.tp.0000278093.58340.fb",
language = "English",
volume = "84",
pages = "527--531",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Alloimmunization to red cell antigens in liver and multivisceral transplant patients

AU - Shariatmadar, Sherry

AU - Pyrsopoulos, Nikolaos T.

AU - Vincek, Vladimir

AU - Noto, Thomas A.

AU - Tzakis, Andreas G.

PY - 2007/8/1

Y1 - 2007/8/1

N2 - BACKGROUND. Alloimmunization to red blood cell (RBC) antigens can significantly impact transfusion support of patients undergoing solid-organ transplantation. This study evaluated the incidence of clinically significant RBC alloantibodies (abs) in 2000 consecutive adults receiving liver (OLTX), intestinal (ITX) or multivisceral (MVT) transplants. METHODS. From January 1991 to May 2006, 2000 patients underwent OLTX (n=1892), MVT (n=74), or ITX (n=34). Blood sample for serologic investigation was submitted to the transfusion service no later than 4 hr before surgery. The presence of clinically significant RBC abs before transplant with subsequent transfusion requirements, the incidence of delayed transfusion reactions, and de novo abs after transplant were evaluated. RESULTS. One hundred fifteen patients (5.75%) had clinically significant RBC abs before transplant, with 56.7% directed against Rh system antigens. Forty-six (40%) had multiple abs. A mean of 18 packed RBC units (U) were transfused per patient. Patients requiring >20 U (n=34) or those with multiple abs received antigen-negative units for the first 5-10 U when antibody was still present, switched to antigen-unscreened units during massive blood loss and returned to antigen-negative units for the last 5-10 U transfused. Twelve patients (0.6%) developed de novo abs posttransplant. Twenty-two (1.1%) had delayed serologic transfusion reaction. All patients were successfully managed without delay in initiation of surgery or hemolytic complications. CONCLUSION. RBC alloimmunization can present a special challenge to solid-organ transplantation. Early serologic testing of the recipient pretransplant and prompt communication between the transfusion service and transplant team facilitates successful transfusion management of these patients.

AB - BACKGROUND. Alloimmunization to red blood cell (RBC) antigens can significantly impact transfusion support of patients undergoing solid-organ transplantation. This study evaluated the incidence of clinically significant RBC alloantibodies (abs) in 2000 consecutive adults receiving liver (OLTX), intestinal (ITX) or multivisceral (MVT) transplants. METHODS. From January 1991 to May 2006, 2000 patients underwent OLTX (n=1892), MVT (n=74), or ITX (n=34). Blood sample for serologic investigation was submitted to the transfusion service no later than 4 hr before surgery. The presence of clinically significant RBC abs before transplant with subsequent transfusion requirements, the incidence of delayed transfusion reactions, and de novo abs after transplant were evaluated. RESULTS. One hundred fifteen patients (5.75%) had clinically significant RBC abs before transplant, with 56.7% directed against Rh system antigens. Forty-six (40%) had multiple abs. A mean of 18 packed RBC units (U) were transfused per patient. Patients requiring >20 U (n=34) or those with multiple abs received antigen-negative units for the first 5-10 U when antibody was still present, switched to antigen-unscreened units during massive blood loss and returned to antigen-negative units for the last 5-10 U transfused. Twelve patients (0.6%) developed de novo abs posttransplant. Twenty-two (1.1%) had delayed serologic transfusion reaction. All patients were successfully managed without delay in initiation of surgery or hemolytic complications. CONCLUSION. RBC alloimmunization can present a special challenge to solid-organ transplantation. Early serologic testing of the recipient pretransplant and prompt communication between the transfusion service and transplant team facilitates successful transfusion management of these patients.

KW - Blood transfusion

KW - Liver transplantation

KW - Multivisceral transplantation

KW - RBC alloantibodies

UR - http://www.scopus.com/inward/record.url?scp=34548167101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548167101&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000278093.58340.fb

DO - 10.1097/01.tp.0000278093.58340.fb

M3 - Article

VL - 84

SP - 527

EP - 531

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 4

ER -